Simponi is an injectable biologic drug that has been approved by U.S. Food and Drug Administration for the treatment of psoriatic arthritis.

What is Simponi?

Simponi (also known by its generic name golimumab) is a TNF-alpha inhibitor that was approved by the FDA in April 2009 to treat adults with active psoriatic arthritis. It is also approved for rheumatoid arthritis and ankylosing spondylitis.

Patients take Simponi by giving themselves an injection under the skin once a month. Simponi is designed to be taken continuously to maintain improvement.

To learn more, please visit the Simponi website.

Treatment Pipeline

Learn about the latest treatment options currently in research.

Get the latest information
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Keep up to date with the psoriatic disease field.

Start reading

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2023 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.